# Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

> **NCT01090622** · PHASE1,PHASE2 · COMPLETED · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 4 (actual)

## Conditions studied

- Primary Erythromelalgia
- Inherited Erythromelalgia

## Interventions

- **DRUG:** XPF-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01090622
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2012-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090622, "Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01090622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*